Reich Kristian's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Feb 29, 2024
- Accession no.
- 0001213900-24-018671
- Filed
- Feb 29, 2024
- Trade date
- Feb 27-28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $6.54M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reich KristianCIK 0001920553 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −29,491 | $55.00 | −$1,622,005 | 2,957,483 | Indirect | |
| Feb 27, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −29,431 | $55.00 | −$1,618,705 | 70,071 | Direct | |
| Feb 28, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −31,910 | $55.00 | −$1,755,050 | 2,925,573 | Indirect | |
| Feb 28, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −28,090 | $55.00 | −$1,544,950 | 41,981 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.